This article has been cited by
1Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
Pravien Rajaram,Alyssa Rivera,Kevin Muthima,Nicholas Olveda,Hubert Muchalski,Qiao-Hong Chen
Molecules.2020;25(10)2448
[DOI]
2Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
Orazio Caffo,Cinzia Ortega,Franco Nolè,Donatello Gasparro,Claudia Mucciarini,Michele Aieta,Vittorina Zagonel,Roberto Iacovelli,Ugo De Giorgi,Gaetano Facchini,Antonello Veccia,Erica Palesandro,Elena Verri,Sebastiano Buti,Giorgia Razzini,Giovanni Bozza,Marco Maruzzo,Chiara Ciccarese,Giuseppe Schepisi,Sabrina Rossetti,Francesca Maines,Stefania Kinspergher,Lucia Fratino,Paola Ermacora,Maurizio Nicodemo,Monica Giordano,Donata Sartori,Daniela Scapoli,Roberto Sabbatini,Giovanni Lo Re,Franco Morelli,Alessandro D’Angelo,Isabella Vittimberga,Paolo Lippe,Francesco Carrozza,Caterina Messina,Luca Galli,Francesca Valcamonico,Camillo Porta,Giovanni Pappagallo,Massimo Aglietta
European Journal of Cancer.2021;155(10)56
[DOI]
3Differential Expression of E2F Transcription Factors and Their Functional and Prognostic Roles in Human Prostate Cancer
Zhaodong Han,Rujun Mo,Shanghua Cai,Yuanfa Feng,Zhenfeng Tang,Jianheng Ye,Ren Liu,Zhiduan Cai,Xuejin Zhu,Yulin Deng,Zhihao Zou,Yongding Wu,Zhouda Cai,Yuxiang Liang,Weide Zhong
Frontiers in Cell and Developmental Biology.2022;10(10)56
[DOI]
4SYNPRED: prediction of drug combination effects in cancer using different synergy metrics and ensemble learning
António J Preto,Pedro Matos-Filipe,Joana Mourão,Irina S Moreira
GigaScience.2022;11(10)56
[DOI]
5Mechanisms of Taxane Resistance
Sara M. Maloney,Camden A. Hoover,Lorena V. Morejon-Lasso,Jenifer R. Prosperi
Cancers.2020;12(11)3323
[DOI]
6Pharmacogenomic Biomarkers in Docetaxel Treatment of Prostate Cancer: From Discovery to Implementation
Reka Varnai,Leena M. Koskinen,Laura E. Mäntylä,Istvan Szabo,Liesel M. FitzGerald,Csilla Sipeky
Genes.2019;10(8)599
[DOI]
7Dual-Functional PLGA Nanoparticles Co-Loaded with Indocyanine Green and Resiquimod for Prostate Cancer Treatment
Wenfeng Lin,Chaoming Li,Naijin Xu,Masami Watanabe,Ruizhi Xue,Abai Xu,Motoo Araki,Ruifen Sun,Chunxiao Liu,Yasutomo Nasu,Peng Huang
International Journal of Nanomedicine.2021;Volume 16(8)2775
[DOI]
8Prostate cancer: molecular and cellular mechanisms and their implications in therapy resistance and disease progression
Ninghan Feng,Jiaoti Huang
Asian Journal of Andrology.2019;21(3)213
[DOI]
9The Andrographolide Analogue 3A.1 Synergizes with Taxane Derivatives in Aggressive Metastatic Prostate Cancers by Upregulation of Heat Shock Proteins and Downregulation of MAT2A-Mediated Cell Migration and Invasion
Taraswi Mitra Ghosh,Teeratas Kansom,Suman Mazumder,Joshua Davis,Ahmed S. Alnaim,Shanese L. Jasper,Chu Zhang,Aedan Bird,Praneet Opanasopit,Amit K. Mitra,Robert D. Arnold
Journal of Pharmacology and Experimental Therapeutics.2022;380(3)180
[DOI]
10Effects of Psychological Intervention on Perioperative Quality of Life and Serum PSA and FPSA Levels of Patients with Prostate Cancer Treated with Integrated Traditional Chinese and Western Medicine
Xifeng Sun,Yi Lu,Hongxia Zhu,Rui Li,Donghua Zhang,Kunfang Pang,Nadeem Khan
Evidence-Based Complementary and Alternative Medicine.2021;2021(3)1
[DOI]
11Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective
Jian Huang,Biyun Lin,Benyi Li
Frontiers in Oncology.2022;12(3)1
[DOI]
Feedback

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal